home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.95 -0.30 (-1.85%)

Streaming Delayed Price Updated: 12:08 PM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

19 20 Next >

HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China

January 23, 2023

From HUTCHMED (China) Limited

Via GlobeNewswire

Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor

January 23, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Named Global Top Employer for Sixth Consecutive Year

January 16, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

A Bullish Sign Appears On Takeda Pharmaceutical's Chart ↗

December 28, 2022

Via Benzinga

Takeda To Add Mid-Stage Autoimmune Disease Candidate For $4B ↗

December 13, 2022

Via Benzinga

Takeda's Dengue Vaccine Candidate Under FDA Priority Review ↗

November 23, 2022

Via Benzinga

Takeda Posts Lower 1H Profit, Lifts FY22 Outlook ↗

October 27, 2022

Via Benzinga

Week In Review: Qitan Raises $101 Million For Nanopore Sequencing Devices ↗

January 14, 2023

Qitan Technology, a Chengdu nanopore sequencing company, completed a $101 million Series C round to support its commercialized nanopore devices. Meanwhile, Japan’s Takeda was approved to launch...

Via Talk Markets

Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC

January 11, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study ↗

January 09, 2023

Via Benzinga

Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

January 09, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks ↗

January 06, 2023

Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.

Via Investor's Business Daily

Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

January 05, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Analyst Bullish On Theseus Pharma's Platform For Gastric Cancer Therapies ↗

December 14, 2022

Via Benzinga

Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics

December 13, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Exelixis' Cabometyx/Tecentriq Combo Misses Overall Survival Goal In Lung Cancer Setting ↗

December 09, 2022

Exelixis Inc (NASDAQ: EXEL) announced that the CONTACT-01 study

Via Benzinga

Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases

December 09, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union

December 08, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing

December 06, 2022

From Singapore Economic Development Board (EDB)A*STAR

Via ACN Newswire

Are Tech Layoffs Going to Be a Headache for Alexandria Real Estate Equities? ↗

November 30, 2022

Tech layoffs are in the news, but life sciences companies seem to be doing better.

Via The Motley Fool

Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease ↗

November 29, 2022

The company says it plans soon to present Phase 2 results and its Phase 3 study design.

Via Investor's Business Daily

Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

November 22, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved ↗

November 22, 2022

This year, the World Health Organization (WHO) announced that cancer has become the leading cause of death worldwide, with the latest data showing that nearly 10 million deaths in 2020 were the result...

Via Benzinga

Why Puma Biotechnology's Shares Jumped 20% on Monday ↗

November 21, 2022

It may have benefited from positive news about another company's drug candidate.

Via The Motley Fool

Takeda's Approved Blood Cancer Drug Hits Primary Goal In Newly-Diagnosed Patient Settings ↗

November 17, 2022

Via Benzinga

Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US

November 17, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade ↗

November 16, 2022

Is now the time to load up on these high-yielding investments?

Via The Motley Fool

European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies

November 11, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Why Denali Therapeutics' Stock Rose 6.6% on Wednesday ↗

November 02, 2022

The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.

Via The Motley Fool

Earnings Scheduled For October 27, 2022 ↗

October 27, 2022

Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com